AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 9.16 |
Market Cap | 40.83B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.32 |
PE Ratio (ttm) | 28.19 |
Forward PE | n/a |
Analyst | Buy |
Ask | 9.17 |
Volume | 17,728,665 |
Avg. Volume (20D) | 6,502,963 |
Open | 9.09 |
Previous Close | 9.10 |
Day's Range | 8.86 - 9.10 |
52-Week Range | 7.89 - 10.80 |
Beta | undefined |
About HLN
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensod...
Analyst Forecast
According to 2 analyst ratings, the average rating for HLN stock is "Buy." The 12-month stock price forecast is $10.47, which is an increase of 16.08% from the latest price.
Next Earnings Release
Analysts project revenue of $11.05B, reflecting a -21.37% YoY shrinking and earnings per share of 0.31, making a 40.91% increase YoY.